The Trump administration has reclassified medical marijuana from Schedule I to Schedule III, easing federal restrictions. This change aligns it with drugs like Tylenol with codeine.
Key points
Trump administration eases rules on medical marijuana
Reclassified from Schedule I to Schedule III
Schedule III includes drugs like Tylenol with codeine
Change aims to increase accessibility for patients
May lead to more research opportunities
A marijuana plant
The Trump administration has reclassified medical marijuana on the federal level, from a Schedule I to a Schedule III drug.
Justin Sullivan/Getty Images
Justin Sullivan/Getty Images
The Trump administration is easing rules on medical marijuana, moving it out of the restrictive Schedule I and into Schedule III — a category shared by drugs such as Tylenol with codeine and anabolic steroids.
Acting Attorney General Todd Blanche announced the move on Thursday, saying it "allows for research on the safety and efficacy of this substance, ultimately providing patients with better care and doctors with more reliable information."
Rescheduling marijuana has been discussed in Washington for years. Here's a guide to what's changing now:
What does Thursday's announcement do?
Q&A
What does the reclassification of medical marijuana mean?
The reclassification means that medical marijuana is now considered less restrictive and can be treated similarly to other Schedule III drugs.
Why did the Trump administration change marijuana's classification?
The administration aimed to ease federal regulations on medical marijuana, making it more accessible for patients.
What are the implications of moving marijuana to Schedule III?
Moving marijuana to Schedule III may lead to increased research opportunities and broader medical use, as it is subject to less stringent regulations.
What other drugs are classified as Schedule III?
Schedule III includes drugs like Tylenol with codeine and anabolic steroids, which are considered to have a lower potential for abuse compared to Schedule I substances.
See every story in News — including breaking news and analysis.
For decades, marijuana has been grouped in the same Schedule I classification of drugs as heroin and LSD and kept under the tightest federal controls. Drugs in the category are seen as not having any accepted medical use and being highly prone to abuse.
But many states have legalized marijuana — both medical (40) and recreational (24). And the Justice Department said Thursday that Blanche's action "recognizes the longstanding regulation of medical marijuana by state governments and the need for a common-sense approach to this reality."
The rescheduling does not immediately affect recreational marijuana. The new policy applies to only two types of marijuana products: ones that are FDA-approved and ones that are regulated under a state medical marijuana license.
In late June, the Drug Enforcement Agency will hold hearings looking at the broader rescheduling of marijuana, not just medical programs, the Justice Department also announced.
The administration says it wants to strengthen medical research but also maintain strict federal controls. And the shift to Schedule III does mean that medical marijuana researchers would no longer have to go through the onerous process of obtaining a Schedule I license to do that work. That process has long been seen as intensely rigorous, including tight laboratory regulations to acquire and study marijuana.
Anti-legalization group Smart Approaches to Marijuana, or SAM, condemned the changes.
"Today's marijuana is more dangerous than previously thought, not less dangerous. And until data shows otherwise, it meets current criteria for Schedule I," the group's president, Kevin Sabet, said in a statement. "It's a drug that should be carefully researched, of course, but not legalized through the backdoor."
What does this mean for marijuana businesses?
Cannabis firms registered in state medical marijuana programs stand to get a huge tax burden lifted.
"I'm paying a full tax bill on my gross margin, which no other company does except for people in our industry," said Sam Brill, CEO of Ascend Wellness Holdings, before the shift was announced. His company operates dispensaries in several states.
And in the past, most financial institutions have refused to provide basic banking services even to state-authorized marijuana businesses, because of potential liability. Companies like Brill's largely operate entirely in cash.
After the new plan was announced, Brill said in a statement to NPR, "While rescheduling is not legalization, and it does not resolve all structural challenges in the industry, it is an important step toward a more transparent and accountable market that supports compliant operators."
Sabet from SAM said the marijuana industry is "the new Big Tobacco" and that "President Trump is welcoming them into the homes of families across this country with open arms."
"There are many ways to increase our knowledge without giving a tax break to Big Weed and sending a confusing message about marijuana's harms to the American public," he said.
What about cannabis consumers?
For lots of consumers, the effects of rescheduling might not seem dramatic at first, unless they're users of medical marijuana.
But somewhere along the line, other policy changes are likely to ripple outward, such as the easing of federal drug testing requirements. The new announcement doesn't mention the possibility of that changing.
The change comes as many states have developed thriving markets for THC — the active ingredient in marijuana. In many parts of the U.S., THC drinks and gummies are already easy to purchase, even in states that haven't legalized marijuana. Since the category was created by a hemp loophole in the 2018 Farm Bill, it has blossomed into a market worth billions of dollars.
How did we get here?
The process of rescheduling marijuana got a boost during the Biden administration. Then, President Trump issued an executive order in December of last year directing the attorney general's office to expedite rescheduling marijuana.
Generally, recategorizing drugs happens via an act of Congress or a formal rule-making process. But Trump's order opened the door to a shortcut that ensures U.S. compliance with international drug treaty obligations. And Blanche invoked that streamlined process to recategorize medical marijuana. But for other changes, the administration says it will take a more traditional approach.
What happens next?
The Trump administration has to balance its desire to move quickly with the need to be able to defend these moves in court, because anti-marijuana groupssuch as SAM have vowed to block rescheduling.
Easing rules for regulated medical marijuana first, before taking up other categories of marijuana, could help clear that legal path.
The DEA plans to hold a new hearing on the proposed rescheduling of marijuana on June 29.
